Supplementary files

Supplementary figure S1. Heatmap showing the different protein expression patterns between groups [breast cancer survivors (n=8); controls (n=10)] at different time points [baseline and post-intervention). Blue color indicates higher and yellow lower protein concentration (z-values). Columns represent each sample in the specific group and the time point, while rows indicate protein names. Supplementary table S1. Between-group baseline comparison in protein levels (NPX) and functional outcomes values between breast cancer survivors (n=10 for protein levels; n=11 for functional outcomes) and controls (n=10). Supplementary table S2. Baseline and post-intervention values in protein levels (NPX) by two groups [breast cancer survivors (n = 8); controls (n = 10)]. Supplementary table S3. Baseline and post - intervention values in protein levels (NPX) by three groups [BCRL diagnosis (n = 4); BCRL risk (n = 4); controls (n = 10)]. Supplementary table S4. Baseline Pearson correlation analysis between protein levels (NPX) and BMI, squat and unilateral chest press values [breast cancer survivors (n = 10); controls (n = 10)]. Supplementary table S5. Baseline Pearson correlation analysis between protein levels and handgrip strength, physical activity levels and cardiorespiratory fitness values [breast cancer survivors (n = 10); controls (n = 10)]. Supplementary table S6. Pearson correlation analysis between changes (Δ) in protein levels and changes (Δ) in BMI, squat, unilateral chest press and handgrip strength values [breast cancer survivors (n = 8); controls (n = 10)]. Supplementary table S7. Pearson correlation analysis between baseline values and changes (Δ) in squat, unilateral chest press and handgrip strength [breast cancer survivors (n = 11); controls (n = 10)] and between baseline values and changes (Δ) in protein levels NPX [breast cancer survivors (n = 8); controls (n = 10)]. Supplementary table S8. Function of proteins that showed significant group-by-time interaction and of proteins that showed higher levels in breast cancer survivors at baseline.